Angiogenic activity of sera from interstitial lung disease patients in relation to angiotensin-converting enzyme activity

Advances in Experimental Medicine and Biology

Volumn 756, Issue , 2013, Pages 213-221

  Zielonka, T M ^a   Zycinska, K ^a   Chorostowska Wynimko, J ^b   Filewska, M ^b   Bialas, B ^b   Obrowski, M H ^a   Radzikowska, E ^b   Skopinska Rozewska, E ^c   Demkow, U ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiogenesis; Angiotensin converting enzyme; Chronic inflammation; Interstitial lung disease; Leukocytes

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ANIMAL TISSUE; BIRD BREEDER LUNG; COLORIMETRY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SARCOIDOSIS; SILICOSIS; SPECTROPHOTOMETRY;

EID: 84867512131     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-4549-0_27     Document Type: Conference Paper

References (43)

1. Antoniou, K. M., Pataka, A., Bouros, D., & Siafakas, N. M. (2007). Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fi brosis. Pulmonary Pharmacology & Therapeutics, 20 , 453-461.
2. ATS. (2000). Idiopathic pulmonary fi brosis: Diagnosis and treatment. International consensus statement. American Journal of Respiratory and Critical Care Medicine, 16 , 646-664.
3. ATS/ERS/WASOG. (1999). Statement on sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 160 , 736-755.
4. Brice, E. A., Friedlander, W., Bateman, E. D., & Kirsch, R. E. (1995). Serum angiotensin-converting enzyme activity, concentration, and speci fi c activity granulomatous disease, tuberculosis and COPD. Chest, 107 , 706-710.
5. Carlesimo, M., Giustini, S., Rossi, A., Bonaccorsi, P., & Calvieri, S. (1995). Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. Journal of the American Academy of Dermatology, 32 , 866-869.
6. Ebrahimian, T. G., Tamarat, R., Diurez, C., Duriez, M., Levy, B. I., & Silvestre, J. S. (2005). Dual effect of angiotensinconverting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 25 , 65-70.
7. Escobar, E., Rodríguez-Reyna, T. S., Arrieta, O., & Sotelo, J. (2004). Angiotensin II, cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer. Current Vascular Pharmacology, 2 , 385-399.
8. Fujiyama, S., Matsubara, H., Nozawa, Y., Maruyama, K., Mori, Y., Tsutsumi, Y., Masaki, H., Uchiyama, Y., Koyama, Y., Nose, A., Iba, O., Tateishi, E., Ogata, N., Jyo, N., Higashiyama, S., & Iwasaka, T. (2001). Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circulation Research, 88 , 22-29.
9. Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., Volpert, O., Bouck, N., & Soff, G. A. (1997). The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proceedings of the National Academy of Sciences of the United States of America, 94 , 10868-10872.
10. Gilbert, S., Steinbrech, D. S., Landas, S. K., & Hunninghake, G. W. (1993). Amounts of angiotensin-converting enzyme mRNA re fl ect the burden of granulomas in granulomatous lung disease. American Review of Respiratory Disease, 148(2), 483-486.
11. Gronhagen-Riska, C., Kurppa, K., Fyhrquist, F., & Selroos, O. (1978). Angiotensin-converting enzyme and lysozyme in silicosis and asbestosis. Scandinavian Journal of Respiratory Diseases, 59 , 228-231.
12. Herr, D., Rodewald, M., Fraser, H. M., Hack, G., Konrad, R., Kreienberg, R., & Wulff, C. (2008). Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecologic Oncology, 109 , 418-425.
13. Hiller, K. H., Ruile, P., Kraus, G., Bauer, W. R., & Waller, C. (2010). Tissue ACE inhibition improves microcirculation in remote myocardium after coronary stenosis: MR imaging study in rats. Microvascular Research, 80 , 484-490.
14. Hooper, N. (1991). Angiotensin converting enzyme: Implications from molecular biology for its physiological functions. The International Journal of Biochemistry, 23 , 641-647.
15. Ino, K., Shibata, K., Kajiyama, H., Nawa, A., Nomura, S., & Kikkawa, F. (2006). Manipulating the angiotensin systemnew approaches to the treatment of solid tumors. Expert Opinion on Biological Therapy, 6 , 243-255.
16. Keane, M. P. (2004). Angiogenesis and pulmonary fi brosis: Feast or famine? American Journal of Respiratory and Critical Care Medicine, 170 , 207-209.
17. Kozak, A., Ergul, A., El-Remessy, A. B., Johnson, M. H., Machado, L. S., Elewa, H. F., Abdelsaid, M., Wiley, D. C., & Fagan, S. C. (2009). Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke, 40 , 1870-1876.
18. Lacasse, Y., Selman, M., Costabel, U., Dalphin, J. C., Ando, M., Morell, F., Erkinjuntti-Pekkanen, R., Muller, N., Colby, T. V., Schuyler, M., Cormier, Y., & HP Study Group. (2003). Clinical diagnosis of hypersensitivity pneumonitis. American Journal of Respiratory and Critical Care Medicine, 168 , 952-958.
19. Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P. A., Murray, L. S., Reid, J. L., & Robertson, J. W. (1998). Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? The Lancet, 352 , 179-184.
20. Lieberman, J. (1975). Elevation of serum angiotensin converting enzyme (ACE) level in sarcoidosis. The American Journal of Medicine, 59 , 365-372.
21. Lieberman, J., & Beutler, E. (1976). Elevation of serum angiotensin-converting enzyme in Gaucher's disease. The New England Journal of Medicine, 294 , 1442-1444.
22. Lieberman, J., & Rea, T. H. (1977). Serum angiotensin-converting enzyme in leprosy and coccidioidomycosis. Annals of Internal Medicine, 87 , 423-425.
23. Lovren, F., Pan, Y., Quan, A., Teoh, H., Wang, G., Shukla, P. C., Levitt, K. S., Oudit, G. Y., Al-Omran, M., Stewart, D. J., Slutsky, A. S., Peterson, M. D., Backx, P. H., Penninger, J. M., & Verma, S. (2008). Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. American Journal of Physiology. Heart and Circulatory Physiology, 295 , H1377-H1384.
24. Mossman, B. T., & Churg, A. (1998). Mechanisms in the pathogenesis of asbestosis and silicosis. American Journal of Respiratory and Critical Care Medicine, 157 , 1666-1680.
25. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., Harrap, S., Poulter, N., Marre, M., Cooper, M., Glasziou, P., Grobbee, D. E., Hamet, P., Heller, S., Liu, L. S., Mancia, G., Mogensen, C. E., Pan, C. Y., Rodgers, A., & Williams, B. (2007). Effects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. The Lancet, 370 , 829-840.
26. Raizada, M. K., & Ferreira, A. J. (2007). ACE2: A new target for cardiovascular disease therapeutics. Journal of Cardiovascular Pharmacology, 50 , 112-119.
27. Saaristo, A., Karpanen, T., & Alitalo, K. (2000). Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene, 19 , 6122-6129.
28. Sanchez de Miguel, L., Neysari, S., Jakob, S., Petrimpol, M., Butz, N., Ban fi , A., Zaugg, C. E., Humar, R., & Battegay, E. J. (2008). B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovascular Research, 80 , 106-113.
29. Sano, H., Hosokawa, K., Kidoya, H., & Takakura, N. (2006). Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 26 , 2673-2680.
30. Shibuya, M. (2001). Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Structure and Function, 26 , 25-35.
31. Sidky, Y. A., & Auerbach, R. (1975). Lymphocyte-induced angiogenesis: A quantitative and sensitive assay for the graft-versus-host reaction. The Journal of Experimental Medicine, 141 , 1084-1100.
32. Skopi?ski, P., Sommer, E., Borowska, A., Hevelke, A., Rogala, E., & Skopi?ska-Rozewska, E. (2001). Angiotensinconverting enzyme activity and angiomodulatory effects of sera in patients with diabetic retinopathy. International Journal of Clinical Pharmacology Research, 21 , 73-78.
33. Tzouvelekis, A., Anevlavis, S., & Bouros, D. (2006). Angiogenesis in interstitial lung diseases: A pathogenetic hallmark or a bystander? Respiratory Research, 25 (7), 82.
34. Wagner, E. J., Sanchez, J., McClintock, J. Y., Jenkins, J., & Moldobaeva, A. (2008). In fl ammation and ischemiainduced lung angiogenesis. American Journal of Physiology. Lung Cellular and Molecular Physiology, 294 , L351-L357.
35. Westermann, D., Schultheiss, H. P., & Tschope, C. (2008). New perspective on the tissue kallikrein-kinin system in myocardial infarction: Role of angiogenesis and cardiac regeneration. International Immunopharmacology, 8 , 148-154.
36. Williams, B., Baker, A. Q., Gallacher, B., & Lodwick, D. (1995). Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension, 25 , 913-917.
37. Yoshiji, H., Kuriyama, S., & Fukui, H. (2002a). Angiotensin-I- converting enzyme inhibitors may be an alternative antiangiogenic strategy in the treatment of liver fi brosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biology, 23 , 348-356.
38. Yoshiji, H., Kuriyama, S., & Fukui, H. (2002b). Perindopril: Possible use in cancer therapy. Anti-Cancer Drugs, 13 , 221-228.
39. Yoshiji, H., Kuriyama, S., Noguchi, R., & Fukui, H. (2004). Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Current Cancer Drug Targets, 4 , 555-567.
40. Zambidis, E. T., Park, T. S., Yu, W., Tam, A., Levine, M., Yuan, X., Pryzhkova, M., & Péault, B. (2008). Expression of angiotensin-converting enzyme (CD143) identi fi es and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 112 , 3601-3614.
41. Zielonka, T. M., Demkow, U., Filewska, M., Bia?as, B., Korczynski, P., Szopinski, J., Soszka, A., & Skopinska-Rozewska, E. (2007a). Angiogenic activity of sera from interstitial lung diseases patients in relation to IL-6, IL-8, IL-12 and TNF a serum level. Central European Journal of Immunology, 32 , 53-60.
42. Zielonka, T. M., Demkow, U., Filewska, M., Golian-Geremek, A., Filewska, M., Zycinska, K., Bialas, B., Wardyn, K., & Skopinska-Rozewska, E. (2007b). TNF a and INF g inducing capacity of sera from interstitial lung diseases patients in relation to its angiogenesis activity. Journal of Physiology and Pharmacology, 58 (Suppl. 5), 767-780.
43. Zielonka, T. M., Demkow, U., Filewska, M., Radzikowska, E., Bialas, B., Filewska, M., Zycinska, K., Obrowski, M. H., Kowalski, J., Wardyn, K., & Skopinska-Rozewska, E. (2010). Angiogenic activity of sera from interstitial lung disease patients in relation to pulmonary function. European Journal of Medical Research, 15 (Suppl. 2), 229-234.